<p>隨着全球市場在潛在降息和經濟指標變化的複雜性中航行，亞洲科技行業吸引了投資者的顯著關注，尤其是在中美貿易關係改善的背景下，中國股市錄得顯著漲幅。在這種情況下，識別高增長科技股需要尋找能夠利用當前市場動態的公司，例如技術進步和有利的監管環境。</p>
<h3>亞洲十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>迅博科技</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.53%</td>
<td>65.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>33.77%</td>
<td>43.92%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>29.67%</td>
<td>32.15%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>富士康工業互聯網</td>
<td>27.61%</td>
<td>27.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金環電子</td>
<td>26.64%</td>
<td>35.16%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>23.36%</td>
<td>30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>25.02%</td>
<td>24.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ALTEOGEN</td>
<td>53.33%</td>
<td>71.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器中的 178 只股票的完整列表。</p>
<p>讓我們回顧一些我們篩選出的顯著股票。</p>
<h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Gan &amp; Lee Pharmaceuticals 是一家生物製藥公司，專注於在中國研發、生產和銷售胰島素類似物原料藥和注射劑，市值為 410.1 億人民幣。</p>
<p><strong>運營：</strong> 公司的主要收入來源於胰島素及相關產品的開發、生產和銷售，收入為 38 億人民幣。</p>
<p>Gan &amp; Lee Pharmaceuticals 作為糖尿病護理高增長領域的參與者，展示了強勁的半年業績，銷售額從 13.1 億人民幣飆升至 20.7 億人民幣，淨收入翻倍至 6.0368 億人民幣。這一財務增長得益於戰略性產品發佈，如在阿根廷新批准的胰島素天冬氨酸注射劑——考慮到該國日益嚴重的糖尿病流行和醫療成本，這一舉措具有重要意義。該公司致力於擴大其在拉丁美洲的市場足跡，彰顯其在應對全球醫療需求方面的積極態度，使其在充滿挑戰的市場動態中具備持續增長的良好前景。</p>
<ul>
<li>點擊這裏深入瞭解 Gan &amp; Lee Pharmaceuticals 的完整分析健康報告。</li>
<li>通過我們的歷史報告獲取 Gan &amp; Lee Pharmaceuticals 的過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603087 截至 2025 年 8 月的盈利和收入增長</p>
<h2>日聯科技集團 (SHSE:688531)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 日聯科技集團有限公司專注於在中國研發、製造和銷售 X 射線技術和智能檢測設備，市值為 96.9 億人民幣。</p>
<p><strong>運營：</strong> 日聯科技集團專注於開發和銷售 X 射線技術和智能檢測設備。該公司在中國運營，利用其在先進成像解決方案方面的專業知識，滿足各種工業應用的需求。</p>
<p>在亞洲繁忙的科技環境中，日聯科技集團憑藉顯著的財務舉措和增長指標脱穎而出。最近，該公司宣佈了一項價值 2000 萬人民幣的股票回購計劃，以增強股權激勵，並調整回購價格以提升股東價值。這一戰略性財務舉措與其 25.8% 的強勁年收入增長和 28.1% 的盈利激增相輔相成，顯著超越了中國市場的平均水平。隨着研發費用與這些增長數據緊密對接，日聯不僅在跟上步伐，還在科技行業內設定了基準，承諾在競爭激烈的行業動態中展現出引人注目的未來軌跡。</p>
<ul>
<li>點擊這裏通過我們的綜合健康報告深入瞭解日聯科技集團的複雜情況。</li>
<li>檢查日聯科技集團的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688531 截至 2025 年 8 月的盈利和收入增長</p>
<h2>武漢達夢數據庫 (SHSE:688692)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 武漢達夢數據庫有限公司專注於在中國提供數據庫產品開發服務，市值為 279.8 億人民幣。</p>
<p><strong>運營：</strong> 該公司的收入主要來自數據處理服務，金額為 11.4 億人民幣。</p>
<p>武漢達夢數據庫在競爭激烈的科技環境中保持了強勁的增長軌跡，過去一年年收入增長 22.6%，盈利增長 28.3%，超越了軟件行業平均下降 0.6% 的水平。儘管面臨挑戰，預計盈利增長略低於中國市場預測的 22.5%，而市場的預測為 25.3%，但其對創新的承諾顯而易見，研發投資與這些財務指標緊密對接。該公司最近的戰略舉措，包括召開特別股東大會和宣佈今天的半年度業績，突顯了其在不斷變化的行業動態中加強市場地位和股東溝通的積極態度。</p>
<ul>
<li>點擊這裏解鎖我們對武漢達夢數據庫股票分析的全面見解。</li>
<li>查看我們的歷史表現報告，以獲取武漢達夢數據庫過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:688692 收入和支出明細截至 2025 年 8 月</p>
<h2>總結</h2>
<ul>
<li>在這裏探索我們亞洲高增長科技和人工智能股票篩選器中的 178 個公司。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>利用 Simply Wall St 最大化您的投資潛力，這是一款提供全球市場洞察的綜合應用，免費使用。</li>
</ul>
<h2>尋找新的視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

日聯科技

<p>亞洲科技行業因美中貿易關係改善和中國股市顯著上漲而吸引了更多投資者的關注。關鍵的高增長科技公司包括 Gan & Lee Pharmaceuticals、日聯科技和武漢大夢數據庫，它們都展現出強勁的收入和盈利增長。Gan & Lee 專注於糖尿病護理，日聯科技專注於 X 射線技術，而武漢大夢則提供數據庫服務。這些公司在當前市場動態和技術進步中處於良好位置，使其成為該地區具有吸引力的投資選擇</p>

<p>As global markets navigate the complexities of potential rate cuts and shifting economic indicators, the Asian tech sector has seen a notable surge in investor interest, particularly as Chinese stock markets have recorded significant gains amid improved U.S.-China trade relations. In this context, identifying high-growth tech stocks involves looking for companies that can capitalize on current market dynamics such as technological advancements and favorable regulatory environments.</p>
<div class="lb-trans"><p>隨着全球市場在潛在降息和經濟指標變化的複雜性中航行，亞洲科技行業吸引了投資者的顯著關注，尤其是在中美貿易關係改善的背景下，中國股市錄得顯著漲幅。在這種情況下，識別高增長科技股需要尋找能夠利用當前市場動態的公司，例如技術進步和有利的監管環境。</p>
</div><h3>Top 10 High Growth Tech Companies In Asia</h3>
<div class="lb-trans"><h3>亞洲十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accton Technology</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.53%</td>
<td>65.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>33.77%</td>
<td>43.92%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>29.67%</td>
<td>32.15%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Foxconn Industrial Internet</td>
<td>27.61%</td>
<td>27.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Gold Circuit Electronics</td>
<td>26.64%</td>
<td>35.16%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>23.36%</td>
<td>30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>25.02%</td>
<td>24.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ALTEOGEN</td>
<td>53.33%</td>
<td>71.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>迅博科技</td>
<td>22.79%</td>
<td>22.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>PharmaEssentia</td>
<td>31.53%</td>
<td>65.34%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>33.77%</td>
<td>43.92%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Eoptolink Technology</td>
<td>29.67%</td>
<td>32.15%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>富士康工業互聯網</td>
<td>27.61%</td>
<td>27.23%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>金環電子</td>
<td>26.64%</td>
<td>35.16%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>盛宜電子</td>
<td>23.36%</td>
<td>30.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>eWeLLLtd</td>
<td>25.02%</td>
<td>24.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ALTEOGEN</td>
<td>53.33%</td>
<td>71.63%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>100.40%</td>
<td>118.16%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 178 stocks from our Asian High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲高增長科技和人工智能股票篩選器中的 178 只股票的完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>讓我們回顧一些我們篩選出的顯著股票。</p>
</div><h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
<div class="lb-trans"><h2>Gan &amp; Lee Pharmaceuticals (SHSE:603087)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Gan &amp; Lee Pharmaceuticals is a biopharmaceutical company focused on the research, development, production, and sale of insulin analog APIs and injections in China, with a market cap of CN¥41.01 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gan &amp; Lee Pharmaceuticals 是一家生物製藥公司，專注於在中國研發、生產和銷售胰島素類似物原料藥和注射劑，市值為 410.1 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's primary revenue stream is derived from the development, production, and sales of insulin and related products, generating CN¥3.80 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的主要收入來源於胰島素及相關產品的開發、生產和銷售，收入為 38 億人民幣。</p>
</div><p>Gan &amp; Lee Pharmaceuticals, a player in the high-growth sector of diabetes care, showcased robust half-year results with sales soaring to CNY 2.07 billion from CNY 1.31 billion and net income doubling to CNY 603.68 million. This financial upswing is backed by strategic product launches like the newly approved insulin aspart injection in Argentina—a significant move considering the country's rising diabetes prevalence and healthcare costs. The firm's commitment to expanding its Latin American footprint underscores its proactive approach in addressing global healthcare needs, positioning it well for sustained growth amidst challenging market dynamics.</p>
<div class="lb-trans"><p>Gan &amp; Lee Pharmaceuticals 作為糖尿病護理高增長領域的參與者，展示了強勁的半年業績，銷售額從 13.1 億人民幣飆升至 20.7 億人民幣，淨收入翻倍至 6.0368 億人民幣。這一財務增長得益於戰略性產品發佈，如在阿根廷新批准的胰島素天冬氨酸注射劑——考慮到該國日益嚴重的糖尿病流行和醫療成本，這一舉措具有重要意義。該公司致力於擴大其在拉丁美洲的市場足跡，彰顯其在應對全球醫療需求方面的積極態度，使其在充滿挑戰的市場動態中具備持續增長的良好前景。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Gan &amp; Lee Pharmaceuticals.</li>
<li>Gain insights into Gan &amp; Lee Pharmaceuticals' past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Gan &amp; Lee Pharmaceuticals 的完整分析健康報告。</li>
<li>通過我們的歷史報告獲取 Gan &amp; Lee Pharmaceuticals 的過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/7a10c09c-0ce0-4521-983e-db4cac70f1be/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:603087 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:603087 截至 2025 年 8 月的盈利和收入增長</p>
</div><h2>Unicomp Technology Group (SHSE:688531)</h2>
<div class="lb-trans"><h2>日聯科技集團 (SHSE:688531)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Unicomp Technology Group Co., Ltd. specializes in the research, development, manufacture, and sale of X-ray technology and intelligent detection equipment in China with a market capitalization of CN¥9.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 日聯科技集團有限公司專注於在中國研發、製造和銷售 X 射線技術和智能檢測設備，市值為 96.9 億人民幣。</p>
</div><p><strong>Operations:</strong> Unicomp Technology Group focuses on developing and selling X-ray technology and intelligent detection equipment. The company operates in China, leveraging its expertise in advanced imaging solutions to cater to various industrial applications.</p>
<div class="lb-trans"><p><strong>運營：</strong> 日聯科技集團專注於開發和銷售 X 射線技術和智能檢測設備。該公司在中國運營，利用其在先進成像解決方案方面的專業知識，滿足各種工業應用的需求。</p>
</div><p>Unicomp Technology Group, amid a bustling tech landscape in Asia, is distinguishing itself with notable financial maneuvers and growth metrics. Recently, the company announced a share repurchase program valued at CNY 20 million to bolster equity incentives, adjusting its buyback price to enhance shareholder value. This strategic financial play complements its robust annual revenue growth of 25.8% and earnings surge of 28.1%, outpacing the Chinese market averages significantly. With R&amp;D expenses aligning closely with these growth figures, Unicomp is not just keeping pace but setting benchmarks within the tech sector, promising an intriguing future trajectory amidst competitive industry dynamics.</p>
<div class="lb-trans"><p>在亞洲繁忙的科技環境中，日聯科技集團憑藉顯著的財務舉措和增長指標脱穎而出。最近，該公司宣佈了一項價值 2000 萬人民幣的股票回購計劃，以增強股權激勵，並調整回購價格以提升股東價值。這一戰略性財務舉措與其 25.8% 的強勁年收入增長和 28.1% 的盈利激增相輔相成，顯著超越了中國市場的平均水平。隨着研發費用與這些增長數據緊密對接，日聯不僅在跟上步伐，還在科技行業內設定了基準，承諾在競爭激烈的行業動態中展現出引人注目的未來軌跡。</p>
</div><ul>
<li>Navigate through the intricacies of Unicomp Technology Group with our comprehensive health report here.</li>
<li>Examine Unicomp Technology Group's past performance report to understand how it has performed in the past.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的綜合健康報告深入瞭解日聯科技集團的複雜情況。</li>
<li>檢查日聯科技集團的歷史表現報告，以瞭解其過去的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/f86d725e-5cf5-4572-9dda-83a9af42fbe8/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:688531 Earnings and Revenue Growth as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:688531 截至 2025 年 8 月的盈利和收入增長</p>
</div><h2>Wuhan Dameng Database (SHSE:688692)</h2>
<div class="lb-trans"><h2>武漢達夢數據庫 (SHSE:688692)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Wuhan Dameng Database Company Limited specializes in database product development services in China and has a market cap of CN¥27.98 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 武漢達夢數據庫有限公司專注於在中國提供數據庫產品開發服務，市值為 279.8 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from data processing services, amounting to CN¥1.14 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自數據處理服務，金額為 11.4 億人民幣。</p>
</div><p>Wuhan Dameng Database has been navigating the competitive tech landscape with a robust growth trajectory, evidenced by a 22.6% annual revenue increase and a 28.3% surge in earnings over the past year, surpassing the software industry's average decline of 0.6%. Despite facing challenges with an expected earnings growth slightly below the Chinese market forecast at 22.5%, compared to the market’s 25.3%, its commitment to innovation is clear with significant R&amp;D investments aligning closely with these financial metrics. The company’s recent strategic moves, including hosting a special shareholders meeting and announcing upcoming half-year results on today's date, underscore its proactive stance in strengthening market position and shareholder communications amidst evolving industry dynamics.</p>
<div class="lb-trans"><p>武漢達夢數據庫在競爭激烈的科技環境中保持了強勁的增長軌跡，過去一年年收入增長 22.6%，盈利增長 28.3%，超越了軟件行業平均下降 0.6% 的水平。儘管面臨挑戰，預計盈利增長略低於中國市場預測的 22.5%，而市場的預測為 25.3%，但其對創新的承諾顯而易見，研發投資與這些財務指標緊密對接。該公司最近的戰略舉措，包括召開特別股東大會和宣佈今天的半年度業績，突顯了其在不斷變化的行業動態中加強市場地位和股東溝通的積極態度。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Wuhan Dameng Database stock in this health report.</li>
<li>Review our historical performance report to gain insights into Wuhan Dameng Database's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們對武漢達夢數據庫股票分析的全面見解。</li>
<li>查看我們的歷史表現報告，以獲取武漢達夢數據庫過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/f68591b8-9a91-4950-910d-cbaccb637d75/chart/revenue-and-expenses-breakdown"/></p>
<p>SHSE:688692 Revenue and Expenses Breakdown as at Aug 2025</p>
<div class="lb-trans"><p>SHSE:688692 收入和支出明細截至 2025 年 8 月</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Explore the 178 names from our Asian High Growth Tech and AI Stocks screener here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們亞洲高增長科技和人工智能股票篩選器中的 178 個公司。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，輕鬆監控您股票的所有重要指標。</li>
<li>利用 Simply Wall St 最大化您的投資潛力，這是一款提供全球市場洞察的綜合應用，免費使用。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新的視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

探索亞洲高增長科技股，精選三大領先選擇